PATENT CLAIM ANALYSIS

Application Number: 15775080
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "04400A"]

Abstract:
Provided is a composition containing an agent capable of inhibiting the expression of HMGCLL1 IS3, and a method for treating or preventing a malignant tumor. The malignant tumor expresses HMGCLL1 IS3. The malignant tumors may show resistance to tyrosine kinase inhibitors. A method, composition, and kit for determining the expression level of HMGCLL1 IS3, for diagnosing drug resistance, for determining the probability of developing a malignant tumor, and for predicting prognosis of malignant tumors are provided.

Claim (Index 6):
The composition of  claim 2 , wherein the polynucleotide comprises any one nucleotide sequence selected from the group consisting of nucleotide sequences of SEQ ID NOS: 5 to 8.

Metadata:
- Claim Count in Document: 10.0
- Percentile: 93.0
- Lexical Diversity: 1.86957
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12708294', '13050604', '14979566', '11317516', '13809880']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8175143596516875
- 35 USC 102 Novelty (BERT): 0.496308608535324
- Combined Prediction Score: 0.7853937845400512
- Mean Citation Score: 232.853344
- Max Citation Score: 236.59807
- Similarity Product: 164.05100142504156

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test